REMARKS

Pursuant to the requirements of 37 C.F.R. §§ 1.821-1.825, Applicants submit the enclosed Sequence Listing and computer readable form (CRF). The amino acid sequences disclosed in the specification and drawings may be found in computer readable form in file 991768.txt on the enclosed diskette and are presented in the paper copy of the Sequence Listing, enclosed.

Applicants hereby certify that the Sequence Listing in computer readable form (CRF) supplied on the enclosed diskette as file 991768.txt is the same as the substitute copy of the Sequence Listing attached hereto. The material presented in computer readable form (CRF) is not new matter because it presents sequences the same as those disclosed in the specification, as filed.

Applicants believe that the requirements of 37 C.F.R. §§ 1.821-1.825 have been met.

Respectfully submitted,

WEBB ZIESENHEIM LOGSDON
ORKIN & HANSON, P.C.

By _____

Barbara E. Johnson
Registration No. 31,198
Attorney for Applicants
700 Koppers Building
436 Seventh Avenue
Pittsburgh, PA 15219-1818
Telephone: 412-471-8815
Facsimile: 412-471-4094

MARKED-UP AMENDED ABSTRACT OF THE DISCLOSURE

The invention relates to the use of ubiquicidine or optionally modified peptide fragments derived therefrom for the preparation of a drug for the treatment, diagnostics or prophylaxis of infections in humans and animals. A peptide fragment derived from ubiquicidine comprises for instance a preferably continuous series of at least 3, preferably at least 7-13 amino acids from the amino acid sequence of ubiquicidine:

KVHGSLARAGKVRGQTPKVAKQEKKKKKTGRAKRRMQYNRRFVNVVPTFGKKKGPN ANS **(SEQ ID NO: 1)**. Hybrid molecules comprise for instance a cationic peptide with an antimicrobial action and/or a peptide fragment of ubiquicidine and/or a derivative thereof and one or more effector molecules.